UBS Group’s Amicus Therapeutics FOLD Stock Holding History

UBS Group’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,255,000	Closed	-$15.2M	–	8123
2018 Q3	$15.2M	Sell	1,255,000 -137,500	-10%	-$1.92M	0.01%	1418
2018 Q2	$21.8M	Buy	1,392,500 +392,500	+39%	+$5.93M	0.01%	1111
2018 Q1	$15M	Buy	+1,000,000	New	+$15.2M	0.01%	1361
2016 Q1	–	Sell	-500	Closed	-$5K	–	7807
2015 Q4	$5K	Hold	500	–	–	﹤0.01%	7686
2015 Q3	$7K	Hold	500	–	–	﹤0.01%	7491
2015 Q2	$7K	Sell	500 -2,600	-84%	-$31.3K	﹤0.01%	7690
2015 Q1	$34K	Sell	3,100 -92,000	-97%	-$811K	﹤0.01%	6421
2014 Q4	$791K	Buy	+95,100	New	+$653K	﹤0.01%	3759

Other funds holding FOLD

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

UBS Group's FOLD Position: Q2 2026 in Review

UBS Group sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 15,957,913 shares — an estimated $231M sold.

UBS Group first reported a position in FOLD in Q4 2014 and held it in 46 quarters. The position peaked at $231M in Q1 2026. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.

UBS Group reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
UBS Group sold 15,957,913 Amicus Therapeutics shares in Q2 2026, an estimated $231M.
UBS Group first reported a position in Amicus Therapeutics in Q4 2014 and held it in 46 quarters.
UBS Group's Amicus Therapeutics position peaked at $231M in Q1 2026.
2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.